Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.

Wang-Gillam, Andrea; Lim, Kian-Huat; McWilliams, Robert; Suresh, Rama; Lockhart, Albert C; Brown, Amberly; Breden, Marcus; Belle, Jad I; Herndon, John; Bogner, Savannah J; Pedersen, Katrina; Tan, Benjamin; Boice, Nicholas; Acharya, Abhi; Abdiannia, Mina; Gao, Feng; Yoon, Harry H; Zhu, Mojun; Trikalinos, Nikolaos A; Ratner, Lee; Aranha, Olivia; Hawkins, William G; Herzog, Brett H; DeNardo, David G

Wang-Gillam, Andrea; Lim, Kian-Huat; McWilliams, Robert; Suresh, Rama; Lockhart, Albert C; Brown, Amberly; Breden, Marcus; Belle, Jad I; Herndon, John; Bogner, Savannah J; Pedersen, Katrina; Tan, Benjamin; Boice, Nicholas; Acharya, Abhi; Abdiannia, Mina; Gao, Feng; Yoon, Harry H; Zhu, Mojun; Trikalinos, Nikolaos A; Ratner, Lee; Aranha, Olivia; Hawkins, William G; Herzog, Brett H; DeNardo, David G.

Clin Cancer Res ; 29(22): 4698, 2023 Nov 14.

Article in En | MEDLINE | ID: mdl-37960920

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Type: Article